Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in <i>BRCA</i> ‐Mutated Advanced Breast Cancer (BROCADE3) Trial-Reference-Cited by-同舟云学术

Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA ‐Mutated Advanced Breast Cancer (BROCADE3) Trial

Published:2022-05-05 Issue:10 Volume:62 Page:1236-1246
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Stodtmann Sven¹,Eckert Doerthe¹,Joshi Rujuta²,Nuthalapati Silpa²,Ratajczak Christine K.³,Menon Rajeev²,Mensing Sven¹,Xiong Hao²

Affiliation:

1. AbbVie Deutschland GmbH Co. KG Clinical Pharmacology and Pharmacometrics Ludwigshafen Ludwigshafen Germany

2. AbbVie Inc. Clinical Pharmacology and Pharmacometrics North Chicago Illinois USA

3. AbbVie Inc. Oncology Development North Chicago Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2061

Reference18 articles.

1. National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes.https://seer.cancer.gov/statfacts/html/breast‐subtypes.html. Published 2021. Accessed September 24 2021.

2. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

3. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

4. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

5. The Genomic Load of Deleterious Mutations: Relevance to Death in Infancy and Childhood

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07

2. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer;Biology;2023-05-09

3. Targeting Breast Cancer: An Overlook on Current Strategies;International Journal of Molecular Sciences;2023-02-11